Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation

British Journal of Haematology

Volumn 123, Issue 4, 2003, Pages 746-747

  Musto, Pellegrino ^a   Carella Jr , Angelo Michele ^a   Greco, Michele Mario ^a   Falcone, Antonietta ^a   Sanpaolo, Grazia ^a   Bodenizza, Carlo ^a   Cascavilla, Nicola ^a   Melillo, Lorella ^a   Carella, Angelo Michele ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Anti CD20; Autologous stem cell transplantation; Multiple myeloma; Rituximab

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ANTIGEN EXPRESSION; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MAINTENANCE DRUG DOSE; MYELOMA; PRIORITY JOURNAL; SALVAGE THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

EID: 0344553476     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04675.x     Document Type: Letter

References (4)

1. Gemmel, C., Cremer, F.W., Weis, M., Witzens, M., Moldenhauer, G., Koniczek, K.H., Imbach, U., Ho, A.D., Moos, M. & Goldschmidt, H. (2002) Anti CD-20 antibody as consolidation therapy in a patients with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Annals of Hematology, 81, 119-123.
2. Hofer, S., Hunziker, S., Dirnhofer, S. & Ludwig, C. (2003) Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma. British Journal of Haematology, 122, 690-691.
3. Treon, S.P. & Anderson, K.C. (2000) The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Seminars in Oncology, 27, 79-85.
4. Treon, S.P., Pilarski, L.M., Belch, A.R., Kelliher, A., Preffer, F.I., Shima, Y., Mitsiades, C.S., Mitsiades, N.S., Szczepek, A.J., Ellman, L., Harmon, D., Grossbard, M.L. & Anderson, K.C. (2002) CD-20 directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. Journal of Immunotherapy, 25, 72-81.